tickdelta
tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

STESteris

Health care · Medical Devices · NYSE

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. 10-K, Item 1

STE quote by TradingView
Headquarters
Dublin, L2
CEO
Daniel A. Carestio
Next results
around Feb 3, 2027
Compare with peers → Embed
All key numbers (40, from the latest 10-K and 10-Q) From EDGAR
EPS (ttm)7.93Sales (ttm)6.2BNet income (ttm)826.9MSales growth+8.7%EPS growth+27.9%Sales Q/Q+8.8%
Free cash flow937.2MGross margin44.6%Oper. margin19.0%Net margin13.4%FCF margin15.2%ROE11.4%
ROA7.7%R&D / sales1.9%Dividend2.46Debt/Eq0.26Curr. ratio2.05Cash531.1M
Op. cash flow (ttm)1.3BEBITDA1.6BEBITDA margin26.8%Net debt1.4BQuick ratio1.53Interest cover18.15
ROIC9.0%Payout ratio31.0%Tax rate25.0%Stock pay / sales1.0%Shares out.97.1MShares Y/Y-0.4%
Book / share74.74Cash / share5.47Sales / share63.49Asset turnover0.58Inventory turns5.24Days sales out.67
Sales 3Y CAGR+9.4%Sales 5Y CAGR+13.8%EPS 3Y CAGR+94.9%EPS 5Y CAGR+11.4%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Changes in the numbers

FY2026 against FY2025
  • Operating margin widened to 18.6%15.9% → 18.6% · Operating income / revenue · 10-K ↗
What management wrote about it → · Every company →

STE against Health care peers

Ten years, side by side → · All 60 →
GrowthProfitBalanceCleanInsiders
STEPeer median

Each side 0 to 100, ranked against every company we cover: relative position on reported figures, not a buy score. How

Every dot is one of the 60 companies, the better end on the right. Hover a dot for the company.

Sales growth
+8.7%24th of 60 · median +7.1%
Net margin
13.4%27th of 60 · median 9.6%
Return on equity
11.4%31st of 54 · median 13.1%
Free cash flow margin
15.2%29th of 56 · median 15.5%
Debt / equity (less is better)
0.269th of 49 · median 0.66
STE and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthGross marginNet marginROEFCF marginDebt / equity
STE Steris$6.2B +8.7%44.6%13.4%11.4%15.2%0.26
A Agilent Technologies$7.4B +6.7%53.8%19.5%19.6%17.2%0.54
EW Edwards Lifesciences$6.7B +11.5%78.0%15.3%9.4%21.3%0.06
INCY Incyte$6.0B +21.2%92.7%6.7%7.1%--
RMD ResMed$5.7B +9.9%61.1%27.8%26.8%28.1%0.07
DXCM Dexcom$5.1B +15.6%63.4%19.4%39.1%21.5%-

From $4.2B of sales to $243.9M of profit

FY2022, from the 10-K income statement
Revenue to Gross profit: $1.9BRevenue to Cost of revenue: $2.3BGross profit to Operating profit: $477.8MGross profit to Operating expenses: $1.4BOperating profit to Net profit: $243.9MOperating profit to Tax & other: $233.9MOperating expenses to R&D: $86.7MOperating expenses to SG&A: $1.3B Revenue: $4.2B Revenue$4.2B +36% Y/Y Gross profit: $1.9B · 45% margin Gross profit$1.9B45% margin +40% Y/Y Cost of revenue: $2.3B · 55% of revenue Cost of revenue$2.3B55% of revenue Operating profit: $477.8M · 11% margin Operating profit$477.8M11% margin −13% Y/Y Operating expenses: $1.4B · 33% of revenue Operating expenses$1.4B33% of revenue Net profit: $243.9M · 6% margin Net profit$243.9M6% margin −39% Y/Y Tax & other: $233.9M · 6% of revenue Tax & other$233.9M6% of revenue R&D: $86.7M · 2% of revenue R&D$86.7M2% of revenue SG&A: $1.3B · 31% of revenue SG&A$1.3B31% of revenue

Swipe sideways for the whole flow →

From $4.5B of sales to $107.0M of profit

FY2023, from the 10-K income statement and revenue by product
Product to Revenue: $2.4BService to Revenue: $2.2BRevenue to Gross profit: $2.0BRevenue to Cost of revenue: $2.6BGross profit to Operating profit: $791.1MGross profit to Operating expenses: $1.2BOperating profit to Net profit: $107.0MOperating profit to Tax & other: $684.1MOperating expenses to R&D: $98.5MOperating expenses to SG&A: $1.1B Product: $2.4B · 52% Product$2.4B52% Service: $2.2B · 48% Service$2.2B48% Revenue: $4.5B Revenue$4.5B +7% Y/Y Gross profit: $2.0B · 44% margin Gross profit$2.0B44% margin +5% Y/Y Cost of revenue: $2.6B · 56% of revenue Cost of revenue$2.6B56% of revenue Operating profit: $791.1M · 17% margin Operating profit$791.1M17% margin +66% Y/Y Operating expenses: $1.2B · 26% of revenue Operating expenses$1.2B26% of revenue Net profit: $107.0M · 2% margin Net profit$107.0M2% margin −56% Y/Y Tax & other: $684.1M · 15% of revenue Tax & other$684.1M15% of revenue R&D: $98.5M · 2% of revenue R&D$98.5M2% of revenue SG&A: $1.1B · 24% of revenue SG&A$1.1B24% of revenue

Swipe sideways for the whole flow →

From $5.1B of sales to $378.2M of profit

FY2024, from the 10-K income statement and revenue by product
Product to Revenue: $2.8BService to Revenue: $2.4BRevenue to Gross profit: $2.2BRevenue to Cost of revenue: $2.9BGross profit to Operating profit: $836.1MGross profit to Operating expenses: $1.4BOperating profit to Net profit: $378.2MOperating profit to Tax & other: $457.9MOperating expenses to R&D: $103.7MOperating expenses to SG&A: $1.3B Product: $2.8B · 54% Product$2.8B54% Service: $2.4B · 46% Service$2.4B46% Revenue: $5.1B Revenue$5.1B +13% Y/Y Gross profit: $2.2B · 43% margin Gross profit$2.2B43% margin +12% Y/Y Cost of revenue: $2.9B · 57% of revenue Cost of revenue$2.9B57% of revenue Operating profit: $836.1M · 16% margin Operating profit$836.1M16% margin +6% Y/Y Operating expenses: $1.4B · 27% of revenue Operating expenses$1.4B27% of revenue Net profit: $378.2M · 7% margin Net profit$378.2M7% margin +253% Y/Y Tax & other: $457.9M · 9% of revenue Tax & other$457.9M9% of revenue R&D: $103.7M · 2% of revenue R&D$103.7M2% of revenue SG&A: $1.3B · 25% of revenue SG&A$1.3B25% of revenue

Swipe sideways for the whole flow →

From $5.5B of sales to $614.6M of profit

FY2025, from the 10-K income statement and revenue by product
Product to Revenue: $2.9BService to Revenue: $2.6BRevenue to Gross profit: $2.4BRevenue to Cost of revenue: $3.1BGross profit to Operating profit: $866.6MGross profit to Operating expenses: $1.5BOperating profit to Net profit: $614.6MOperating profit to Tax & other: $252.0MOperating expenses to R&D: $107.6MOperating expenses to Sales, admin & other: $1.4B Product: $2.9B · 53% Product$2.9B53% Service: $2.6B · 47% Service$2.6B47% Revenue: $5.5B Revenue$5.5B +6% Y/Y Gross profit: $2.4B · 44% margin Gross profit$2.4B44% margin +8% Y/Y Cost of revenue: $3.1B · 56% of revenue Cost of revenue$3.1B56% of revenue Operating profit: $866.6M · 16% margin Operating profit$866.6M16% margin +4% Y/Y Operating expenses: $1.5B · 28% of revenue Operating expenses$1.5B28% of revenue Net profit: $614.6M · 11% margin Net profit$614.6M11% margin +63% Y/Y Tax & other: $252.0M · 5% of revenue Tax & other$252.0M5% of revenue R&D: $107.6M · 2% of revenue R&D$107.6M2% of revenue Sales, admin & other: $1.4B · 26% of revenue Sales, admin & other$1.4B26% of revenue

Swipe sideways for the whole flow →

From $5.9B of sales to $782.3M of profit

FY2026, from the 10-K income statement and revenue by product
Product to Revenue: $3.1BService to Revenue: $2.9BRevenue to Gross profit: $2.6BRevenue to Cost of revenue: $3.3BGross profit to Operating profit: $1.1BGross profit to Operating expenses: $1.5BOperating profit to Net profit: $782.3MOperating profit to Tax & other: $319.5MOperating expenses to R&D: $112.9MOperating expenses to SG&A: $1.4B Product: $3.1B · 52% Product$3.1B52% Service: $2.9B · 48% Service$2.9B48% Revenue: $5.9B Revenue$5.9B +9% Y/Y Gross profit: $2.6B · 44% margin Gross profit$2.6B44% margin +9% Y/Y Cost of revenue: $3.3B · 56% of revenue Cost of revenue$3.3B56% of revenue Operating profit: $1.1B · 19% margin Operating profit$1.1B19% margin +27% Y/Y Operating expenses: $1.5B · 26% of revenue Operating expenses$1.5B26% of revenue Net profit: $782.3M · 13% margin Net profit$782.3M13% margin +27% Y/Y Tax & other: $319.5M · 5% of revenue Tax & other$319.5M5% of revenue R&D: $112.9M · 2% of revenue R&D$112.9M2% of revenue SG&A: $1.4B · 24% of revenue SG&A$1.4B24% of revenue

Swipe sideways for the whole flow →

Where each $100 of sales went

FY2022
FY2023
FY2024
FY2025
FY2026
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement →

Profitability

3 of 4
  • ✓
    Net margin above the peer median13.4% vs 9.6%
  • ✓
    Gross margin up over 5 years43.2% → 44.2%
  • !
    Return on equity below 15%11.4%
  • ✓
    A profit in every one of 10 years
Net margin, FY2017 to FY2026: 4.2% → 13.2%

Balance sheet

4 of 4
  • ✓
    Interest covered more than 5 timesOperating income is 18.2× interest expense
  • ✓
    Debt smaller than equityDebt / equity 0.26 on the latest balance sheet (peer median 0.66)
  • ✓
    Current assets cover current liabilitiesCurrent ratio 2.05
  • ✓
    Net debt under 3 years of free cash flow$1.4B net debt, 1.5 years
Debt / equity at each year end, FY2017 to FY2026: 0.41 → 0.27
What the debt is made of ↓

Cash and shareholders

3 of 4
  • ✓
    Free cash flow positive in every one of 10 years$972.4M last year
  • !
    Share count up over 5 years+14.9%
  • ✓
    Dividend per share up over 5 years$1.57 → $2.46
  • ✓
    Cash from operations above net income$1.3B vs $782.3M
Free cash flow, FY2017 to FY2026: 251.2M → 972.4M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

What the debt is made of, and when it is due

balance sheet of Sep 30, 2026 · schedule of Mar 31, 2026
Debt: $1.9B Debt$1.9B Long-term debt: $1.7B · 85% Long-term debt$1.7B · 85% Short-term borrowings: $243.1M · 12% Short-term borrowings$243.1M · 12% Next 12 months: $118.9M · 6% Next 12 months$118.9M · 6% Year 2: $150.0M · 8% Year 2$150.0M · 8% Year 3: $127.5M · 7% Year 3$127.5M · 7% Year 4: $37.8M · 2% Year 4$37.8M · 2% After year 5: $1.5B · 78% After year 5$1.5B · 78%

The debt note's own lines, 2026-03-31

Line, as the company names itKindRateFixed or floatingAmount
Senior NotesNotes and bonds–not stated$557.8M
STE 3.45% due 2025 Senior NotesNotes and bonds3.45%not stated$125.0M
STE 3.55% due 2027 Senior NotesNotes and bonds3.55%not stated$125.0M
STE 3.70% due 2030 Senior NotesNotes and bonds3.70%not stated$100.0M
STE 1.86% due 2027 Senior NotesNotes and bonds1.86%not stated$68.9M
STE 3.04% due 2029 Senior NotesNotes and bonds3.04%not stated$59.5M
STE 3.93% due 2027 Senior NotesNotes and bonds3.93%not stated$50.0M
STE 4.03% due 2029 Senior NotesNotes and bonds4.03%not stated$45.0M
STE 3.17% due 2032 Senior NotesNotes and bonds3.17%not stated$39.7M
STE 4.05% due 2027 Senior NotesNotes and bonds3.55%not stated$25.0M
STE 2.04% due 2029 Senior NotesNotes and bonds2.04%not stated$23.0M
STE 2.30% due 2032 Senior NotesNotes and bonds2.30%not stated$21.8M
All 12 lines

From the debt note in the 10-K's XBRL (0001628280-26-039136), as the company tags it: by issue, by year, by currency or by kind. Lines from two ways of cutting the same debt can overlap, so they are not added up. Fixed or floating is read from the line's own name only; "not stated" when it says neither.

Left: the debt lines on the balance sheet (XBRL). Right: the principal due each year, from the debt note's maturity schedule; it can differ a little from the balance sheet, which shows the debt net of discounts and fees. Leases are not counted. The full schedule →

Revenue and net income, FY2017 to FY2026

Revenue 5.9B Net income 782.3M
FY2017 revenue 2.6B · Revenues, 0001757898-19-000005 FY2017 net income 110.0M · NetIncomeLoss, 0001757898-19-000005 2.6B FY2017 FY2018 revenue 2.6B · Revenues, 0001757898-20-000012 FY2018 net income 290.9M · NetIncomeLoss, 0001757898-20-000012 2.6B FY2018 FY2019 revenue 2.8B · Revenues, 0001757898-21-000017 FY2019 net income 303.7M · NetIncomeLoss, 0001757898-21-000017 2.8B FY2019 FY2020 revenue 3.0B · Revenues, 0001757898-22-000011 FY2020 net income 407.7M · NetIncomeLoss, 0001757898-22-000011 3.0B FY2020 FY2021 revenue 3.1B · Revenues, 0001757898-23-000005 FY2021 net income 397.4M · NetIncomeLoss, 0001757898-23-000005 3.1B FY2021 FY2022 revenue 4.2B · Revenues, 0001757898-24-000008 FY2022 net income 243.9M · NetIncomeLoss, 0001757898-24-000008 4.2B FY2022 FY2023 revenue 4.5B · Revenues, 0001757898-25-000005 FY2023 net income 107.0M · NetIncomeLoss, 0001757898-25-000005 4.5B FY2023 FY2024 revenue 5.1B · Revenues, 0001628280-26-039136 FY2024 net income 378.2M · NetIncomeLoss, 0001628280-26-039136 5.1B FY2024 FY2025 revenue 5.5B · Revenues, 0001628280-26-039136 FY2025 net income 614.6M · NetIncomeLoss, 0001628280-26-039136 5.5B FY2025 FY2026 revenue 5.9B · Revenues, 0001628280-26-039136 FY2026 net income 782.3M · NetIncomeLoss, 0001628280-26-039136 5.9B FY2026

From XBRL in each 10-K. Hover a bar for the line item and filing. Full financials →

STE's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Annual Quarterly
Revenue5.9B
FY2017: 2.6BFY2018: 2.6BFY2019: 2.8BFY2020: 3.0BFY2021: 3.1BFY2022: 4.2BFY2023: 4.5BFY2024: 5.1BFY2025: 5.5BFY2026: 5.9B FY2018FY2020FY2022FY2024FY2026
Net income782.3M
FY2017: 110.0MFY2018: 290.9MFY2019: 303.7MFY2020: 407.7MFY2021: 397.4MFY2022: 243.9MFY2023: 107.0MFY2024: 378.2MFY2025: 614.6MFY2026: 782.3M FY2018FY2020FY2022FY2024FY2026
Free cash flow972.4M
FY2017: 251.2MFY2018: 292.2MFY2019: 349.8MFY2020: 376.0MFY2021: 450.4MFY2022: 397.2MFY2023: 395.0MFY2024: 613.0MFY2025: 778.0MFY2026: 972.4M FY2018FY2020FY2022FY2024FY2026
EPS (diluted)7.93
FY2017: 1.28FY2018: 3.39FY2019: 3.55FY2020: 4.76FY2021: 4.63FY2022: 2.48FY2023: 1.07FY2024: 3.81FY2025: 6.20FY2026: 7.93 FY2018FY2020FY2022FY2024FY2026
Dividend per share2.46
FY2017: 1.09FY2018: 1.21FY2019: 1.33FY2020: 1.45FY2021: 1.57FY2022: 1.69FY2023: 1.84FY2024: 2.03FY2025: 2.23FY2026: 2.46 FY2018FY2020FY2022FY2024FY2026
Diluted shares98.7M
FY2017: 86.1MFY2018: 85.7MFY2019: 85.5MFY2020: 85.6MFY2021: 85.9MFY2022: 98.3MFY2023: 100.2MFY2024: 99.4MFY2025: 99.1MFY2026: 98.7M FY2018FY2020FY2022FY2024FY2026

Revenue by business segment

year to Mar 31, 2026
RevenueSharevs year before
Healthcare 4.2B70.9% +8.5%
Applied Sterilization Technologies 1.1B19.2% +9.6%
Life Science Member 588.8M9.9% +8.6%

10-K 0001628280-26-039136, segment and revenue notes (XBRL).

Revenue by product or service

year to Mar 31, 2026
RevenueSharevs year before
Product 3.1B51.6% +6.6%
Service 2.9B48.4% +11.1%

10-K 0001628280-26-039136, segment and revenue notes (XBRL).

Revenue by region

year to Mar 31, 2026
RevenueSharevs year before
UNITED STATES 4.3B73.0% +8.1%
Other foreign locations 1.5B25.2% +11.1%
IRELAND 108.5M1.8% +1.1%

10-K 0001628280-26-039136, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue2.6B2.6B2.8B3.0B3.1B4.2B4.5B5.1B5.5B5.9B
Cost of revenue1.6B1.5B1.6B1.7B1.8B2.3B2.6B2.9B3.1B3.3B
Gross profit1.0B1.1B1.2B1.3B1.3B1.9B2.0B2.2B2.4B2.6B
R&D59.4M60.8M63.0M65.5M66.3M86.7M98.5M103.7M107.6M112.9M
SG&A682.0M632.0M669.9M716.7M731.3M1.3B1.1B1.3B1.3B1.4B
Operating income226.2M399.9M411.0M537.0M548.4M477.8M791.1M836.1M866.6M1.1B
Interest expense44.5M50.6M45.0M40.3M37.2M89.5M108.0M144.4M86.3M60.7M
Pretax income184.6M355.0M369.0M498.8M517.5M366.8M680.3M702.8M796.2M1.0B
Income tax74.0M63.4M64.3M90.9M120.7M82.3M124.1M149.5M184.7M262.2M
Net income110.0M290.9M303.7M407.7M397.4M243.9M107.0M378.2M614.6M782.3M
EPS (diluted)1.283.393.554.764.632.481.073.816.207.93
Diluted shares86.1M85.7M85.5M85.6M85.9M98.3M100.2M99.4M99.1M98.7M
Depreciation & amortization188.1M178.3M225.9M197.2M219.2M553.1M552.9M565.2M476.2M486.5M
EBITDA414.3M578.2M636.9M734.3M767.6M1.0B1.3B1.4B1.3B1.6B
Gross margin39.3%41.7%42.2%43.6%43.2%44.6%43.7%43.2%44.0%44.2%
Operating margin8.7%15.3%14.8%17.7%17.6%11.3%17.4%16.3%15.9%18.6%
Net margin4.2%11.1%10.9%13.5%12.8%5.8%2.4%7.4%11.3%13.2%
Revenue growth-+0.3%+6.2%+8.9%+2.5%+35.9%+7.4%+13.3%+6.2%+8.7%
EPS growth-+165%+4.7%+34.1%-2.7%-46.4%-56.9%+256%+62.7%+27.9%

Balance sheet

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Cash282.9M201.5M220.6M319.6M220.5M348.3M208.4M207.0M171.7M439.6M
Receivables-528.1M564.8M586.5M609.4M799.0M865.0M1.0B1.0B1.1B
Inventory-205.7M208.2M263.5M315.1M575.0M604.4M674.5M581.3M631.8M
Current assets-989.7M1.1B1.2B1.2B1.9B2.0B2.9B2.0B2.4B
Property & equipment-1.0B1.0B1.1B1.2B1.6B1.6B1.8B2.0B2.2B
Goodwill2.2B2.4B2.3B2.4B3.0B3.9B3.9B4.1B4.1B4.2B
Total assets-5.2B5.1B5.4B6.6B11.4B10.8B11.1B10.1B10.7B
Accounts payable-135.9M152.9M149.3M156.9M225.7M264.2M251.7M280.8M338.8M
Current liabilities-398.5M465.2M503.6M577.9M922.2M861.8M931.1M1.0B1.1B
Total debt-1.3B1.2B1.2B1.7B3.1B3.1B3.2B2.0B1.9B
Total liabilities-2.0B1.9B2.0B2.7B4.9B4.7B4.7B3.5B3.5B
Shareholders' equity2.8B3.2B3.2B3.4B3.9B6.5B6.1B6.3B6.6B7.2B
Retained earnings-1.1B1.3B1.7B1.9B2.0B1.9B2.1B2.5B3.0B

Cash flow

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating cash flow424.1M457.6M539.5M590.6M689.6M684.8M756.9M973.3M1.1B1.3B
Capital spending172.9M165.5M189.7M214.5M239.3M287.6M362.0M360.3M370.1M369.0M
Free cash flow251.2M292.2M349.8M376.0M450.4M397.2M395.0M613.0M778.0M972.4M
Stock-based pay (added back)18.8M22.2M24.0M23.8M26.0M57.7M39.0M56.5M57.4M61.7M
Dividends paid93.2M102.9M112.5M123.0M133.8M163.2M183.5M200.6M219.9M241.8M
Buybacks97.5M65.5M81.5M51.2M14.6M55.8M308.6M11.8M211.3M235.5M
Acquisitions65.6M46.3M13.3M109.8M909.2M550.4M42.6M546.3M54.1M20.1M
Debt raised--00550.0M650.0M00--
Debt repaid172.5M222.5M85.0M035.0M-----
Investing cash flow-104.3M-203.8M-213.2M-319.7M-1.2B-666.6M-383.3M-887.4M388.8M-512.5M
Financing cash flow-267.1M-356.2M-294.8M-163.1M345.6M115.8M-498.7M-85.2M-1.6B-568.2M
Dividend per share1.091.211.331.451.571.691.842.032.232.46

Stock-based pay and leases

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Stock-based pay (expense)18.8M22.2M24.0M23.8M26.0M57.7M39.0M56.5M57.4M61.7M
Stock-based pay / revenue0.7%0.8%0.9%0.8%0.8%1.4%0.9%1.1%1.1%1.0%
Operating lease cash paid---27.6M29.8M45.1M45.2M46.9M46.5M45.2M
Right-of-use assets--0131.8M150.1M188.5M166.6M173.2M156.4M155.2M
Operating lease liabilities----152.4M191.5M169.6M177.1M158.8M155.4M
Finance lease liabilities----0-----

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Work on STE in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/STE/export.csv") into a cell.